Celixir
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Banbury Rd, Stratford Upon Avon, West Mi...Phone Number
+44 2900000000Website
www.celixir.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Celixir
Celixir is a privately owned UK biotechnology company that discovers and develops life-saving and life-altering advanced therapies for patients with the greatest medical need. Celixir, founded in 2009, is made up of a world class team of scientists and biopharmaceutical executives, led by Nobel Laureate Professor Sir Martin Evans and former Roche Global Head of Emerging Technologies, Ajan Reginald. Celixir's unique platform technology allows it to adopt an 'off-the-shelf' approach to deliver cell therapies to patients. The Company has a partnership with Daiichi Sankyo in which the Japanese pharmaceutical company undertakes all development, regulatory and commercial activities for Celixir's immunomodulatory progenitor cells in Japan. Celixir retains worldwide rights outside of Japan and global manufacturing responsibilities.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Celixir your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Celixir has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Celixir launches new products
Check out if Celixir is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Celixir
Funding: Get notified immidiatlly once Celixir has new funding data
Click to see if Celixir had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Celixir, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Celixir recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Celixir as Masked Content
Find 2 more new buyers
Compare Similar Companies to Celixir
Compare insights from companies similar to Celixir, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Celixir
<$5M
11-50
Private
-
2009
N/A
Company Profile Activity
Activity Insights
Celixir is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Celixir is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Celixir.
Celixir Tech Stack
A closer look at the technologies used by Celixir
Celixir News & Media
Celixir publishes positive study results for potential cancer gene therapies showing cancer cell reduction in colon and breast cancer cell lines
Celixir publishes positive study results for potential cancer gene therapies showing cancer cell reduction in colon and breast cancer cell linesCelixir announces US FDA approval of the IND application for cell therapy Heartcel
Celixir announces US FDA approval of the IND application for cell therapy HeartcelTM
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Celixir
Sign Up For FreeTo access detailed company insights
Celixir is a privately owned UK biotechnology company that discovers and develops life-saving and life-altering advanced therapies for patients with the greatest medical need. Celixir, founded in 2009, is made up of a world class team of scientists and biopharmaceutical executives, led by Nobel Laureate Professor Sir Martin Evans and former Roche G... Read More
